PFE  Pfizer Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

-0.6601 (-1.9716%)

Growth Price

Overvalued by 12.33%

Stability Price

Overvalued by 63.47%

Company Metrics

  • P/E 23.293
  • P/S 4.2842
  • P/B 3.088
  • EPS 1.409
  • Cash ROIC 12.30%
  • Cash Ratio 1.67
  • Dividend 1.12 / 3.39%
  • Avg. Vol. 25.79M
  • Shares 6.17B
  • Market Cap. 202.41B

Company Description

Pfizer Inc., a biopharmaceutical company, offers prescription medicines for humans and animals worldwide. The company's Biopharmaceutical segment's provides Lipitor for elevated LDL-cholesterol levels in the blood; Enbrel for rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis; Lyrica for post-herpetic neuralgia, diab... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Pfizer Inc. Upgraded To “Overweight” At Morgan Stanley: Here's Why
Bidness ETC - 19 hours ago
In a report published on Friday, October 2, Morgan Stanley upgraded Pfizer Inc. (NYSE:PFE) stock from Equal-weight to Overweight, and boosted its 12-month price target on the stock from $35.00 to $38.00.
Pfizer raised prices on 133 drugs this year, and it's not alone - Livemint
Pfizer, Inc. (NYSE:PFE) Analyst Price Target
Money Flow Index - 23 hours ago
Pfizer, Inc. (NYSE:PFE) shares are expected to touch $39.44 in the short term. This short term price target has been shared by 9 analysts.
Shares of Pfizer, Inc. (NYSE:PFE) Sees Large Inflow of Net Money - News Watch International
Pfizer Downgraded by Vetr Inc. (PFE) - Dakota Financial News
Company Shares of Pfizer, Inc. (NYSE:PFE) Rally 3.73%
News Watch International - Oct 5, 2015
Shares of Pfizer, Inc. (NYSE:PFE) rose by 3.73% in the past week and 5.45% for the last 4 weeks. In the past week, the shares have outperformed the S&P 500 by 2.67% and the outperformance increases to 3.82% for the last 4 weeks.
Hot Healthcare Stocks: Pfizer Inc. (NYSE:PFE), Merck & Co. Inc. (NYSE:MRK ... - Benchmark Monitor
Drug Manufacturer Most Active- Pfizer Inc. (NYSE:PFE), Merck & Co. Inc. (NYSE ... - StreetWise Report (press release)
Pfizer Inc. Announces Final Results of Exchange Offers
MarketWatch - Oct 2, 2015
NEW YORK, Oct 02, 2015 (BUSINESS WIRE) -- Pfizer Inc. (“Pfizer”) PFE, +3.89% announced today the final results of its previously announced offers to exchange any and all validly tendered and accepted notes of each series listed in the table below ...
Pfizer Inc. (NYSE:PFE) is a Buy at Current Levels – Jim Cramer
LearnBonds - Oct 2, 2015
Encouragingly, Pfizer Inc. (NYSE:PFE)'s well-established product portfolio will remain patent-protected for several more years.
Is This a Stock Shaking News for Pfizer Inc. (PFE)? -
Pfizer Inc (NYSE:PFE) Upgraded at Morgan Stanley to Overweight from Equal ... -
Pfizer Inc (PFE) Closes 2.06% Down on the Day for October 06 - 9 hours ago
Dow Jones component Pfizer Inc ($PFE) saw its stock move -2.06% to $32.79, representing a per-share move of $0.69, on volume of 36.32 million shares for Tuesday.
Pfizer Inc. (PFE) Raises Guidance Upon Hospira Acquisition
Bidness ETC - Oct 1, 2015
On Wednesday, Pfizer Inc. (NYSE:PFE) increased its full year 2015 guidance for revenue and adjusted earnings, driven by the company's acquisition of Hospira Inc. which was closed earlier this month.
Pfizer, Inc. (NYSE:PFE) Analyst Rating Update - Money Flow Index
Pfizer (PFE) Stock Closes Higher, Raises Full-Year Revenue, Earnings Forecasts -
Where is Pfizer, Inc. (NYSE:PFE)s Stock Headed?
Markets Daily - 16 hours ago
Analysts covering shares of Pfizer, Inc. (NYSE:PFE) are anticipating that the stock will trade in the range of $34 to $51 within the next 12 months.
Pfizer Edges Outlook Higher to Factor in Hospira
Wall Street Journal - Sep 30, 2015
Pfizer acquired smaller rival Hospira in a $16 billion deal that closed earlier this month. The acquisition is expected to transform the pharmaceutical company into a leading player in the emerging market for lower-priced knockoffs of costly biotech drugs.
Pfizer (PFE) Boosts FY15 Outlook Following Completion of Hospira Acquisition -
Pfizer lifts outlook to factor in Hospira purchase - MarketWatch
BIND Therapeutics Announces Pfizer Inc. Exercises Option to Advance ...
MarketWatch - Sep 24, 2015
CAMBRIDGE, Mass., Sep 24, 2015 (BUSINESS WIRE) -- BIND Therapeutics, Inc. BIND, +4.19% a clinical-stage nanomedicine company developing targeted and programmable therapeutics called AccurinsTM, today announced that Pfizer Inc. exercised its ...
BIND Therapeutics Announces Pfizer Obtains License for Drug - Pharmaceutical Processing
Pfizer to develop cancer drug partnered with Cambridge biotech Bind - Boston Business Journal (blog)